Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease

Myelodysplastic syndromes (MDS) are a heterogeneous clonal disease of myeloid neoplasms characterized by ineffective hematopoiesis, variable degree of cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). Molecular and genetic characterization of MDS has led to a better u...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohty, Razan, Al Hamed, Rama, Bazarbachi, Ali, Brissot, Eolia, Nagler, Arnon, Zeidan, Amer, Mohty, Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429775/
https://www.ncbi.nlm.nih.gov/pubmed/36045390
http://dx.doi.org/10.1186/s13045-022-01346-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429775/
https://www.ncbi.nlm.nih.gov/pubmed/36045390
http://dx.doi.org/10.1186/s13045-022-01346-9

Ejemplares similares